These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 24828856)

  • 1. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
    Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
    J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
    Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ;
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study.
    Zhou Y; He H; Wang P; Zhang T; Lin M; Wang H; Nie Y; Chen Y
    Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1270-5. PubMed ID: 26275085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
    Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S
    Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
    Steenholdt C; Molazahi A; Ainsworth MA; Brynskov J; Østergaard Thomsen O; Seidelin JB
    Scand J Gastroenterol; 2012 May; 47(5):518-27. PubMed ID: 22375898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience.
    Yamada S; Yoshino T; Matsuura M; Minami N; Toyonaga T; Honzawa Y; Tsuji Y; Nakase H
    BMC Gastroenterol; 2014 Apr; 14():80. PubMed ID: 24758588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
    Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
    Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus.
    Tsukamoto H; Tanida S; Mizoshita T; Ozeki K; Ebi M; Shimura T; Mori Y; Kataoka H; Kamiya T; Joh T
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):714-8. PubMed ID: 23411870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of disease may predict response to infliximab in pediatric ulcerative colitis.
    Mir SA; Nagy-Szakal D; Smith EO; Gilger MA; Kellermayer R
    J Clin Gastroenterol; 2014 Mar; 48(3):248-52. PubMed ID: 24129407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of infliximab in moderate to severe ulcerative colitis in a latin american referral population.
    Juliao F; Marquez J; Aristizabal N; Yepes C; Zuleta J; Gisbert JP
    Digestion; 2013; 88(4):222-8. PubMed ID: 24281150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.
    Vahabnezhad E; Rabizadeh S; Dubinsky MC
    Inflamm Bowel Dis; 2014 Apr; 20(4):606-13. PubMed ID: 24552827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers.
    Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
    Eur J Intern Med; 2014 Oct; 25(8):757-61. PubMed ID: 25086677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological healing after infliximab induction therapy in children with ulcerative colitis.
    Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
    World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience.
    Laharie D; Filippi J; Roblin X; Nancey S; Chevaux JB; Hébuterne X; Flourié B; Capdepont M; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2013 May; 37(10):998-1004. PubMed ID: 23521659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience.
    Nuki Y; Esaki M; Asano K; Maehata Y; Umeno J; Moriyama T; Nakamura S; Matsumoto T; Kitazono T
    Scand J Gastroenterol; 2016; 51(6):700-5. PubMed ID: 26818468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does infliximab prevent colectomy in acute and chronic active ulcerative colitis?
    Dan-Nielsen S; Wewer V; Paerregaard A; Hansen LF; Nielsen RG; Lange A; Jakobsen C
    J Pediatr Gastroenterol Nutr; 2014 Jun; 58(6):768-72. PubMed ID: 24572593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis.
    Löwenberg M; Duijvis NW; Ponsioen C; van den Brink GR; Fockens P; D'Haens GR
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1240-6. PubMed ID: 25171024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
    Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
    Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.